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Summary We evaluated the protective ability of amifostine on peripheral blood mononuclear cell (PBMC)-derived colony-forming unit (CFU)
and PB CD34+ cells which were previously exposed in vitro to etoposide, carboplatin, doxorubicin and taxotere. Amifostine pretreatment
protected PBMC-derived CFU from the toxic effect of etoposide, carboplatin and taxotere. A significant detrmental effect was exerted by
amifostine on the growth of doxorubicin-treated PBMC-derived CFU. Liquid cultures of PB CD34+ cells reproduced faithfully the effects
observed on growth of PBMC-derived CFU and confirmed amifostine chemoprotection against etoposide and carboplatin with its detrimental
effect on doxorubicin-treated progenitors. Combining the data of viable cell count, cytometric estimation ofapoptosis. cell cycle and viable cell
replication rate, we found that amifostine protects from etoposide and carboplatin toxicity mainly through a mechanism of cell rescue.
Conversely, the detrimental effect of amifostine on the growth of doxorubicin-treated PB CD34+ cells is apparently due to an increased G/M
arrest. In conclusion, amifostine protects haematopoietic progenitors from etoposide, carboplatin and taxotere. Progenitor rescue is the
mechanism through which amifostine reduced etoposide and carboplatin toxicity.
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Amifostine is an organic thiophosphate x hich show-s specific
protective activity against the cytotoxicity induced in non-
neoplastic tissues by sexveral chemotherapeutic substances as well
as by radiation therapy (Yuhas and Storer. 1969: Yuhas. 1979:
Yuhas et al. 1980a. 1980b). Amifostine is a pro-drug that is trans-
formed via dephosphorx lation into a free thiol by alkaline phos-
phatase. This occurs at the capillary lexvel. and is mainiv confined
to normal tissues because thev are more vascularized than
neoplastic tissues and because of their greater ability to dephos-
phorvlate amifostine to the free thiol because of a more neutral
intracellular environment then the acidic pH found in many
tumours (Calabro-Jones et al. 1985: 1988). Cell protection from
toxic damage seems to be mediated bv the antioxidant capacity of
thiol (Ohnishi et al. 1992). although additional mechanisms of
protection have also been described (Treskes and van der Vijgh.
1993: Purdie and Inhaber. 1983: Willson. 1983). Preclinical
studies in mice showed that amifostine pretreatment consistently
decreases the toxic effect ofradiation. nitrogen mustards. cisplatin.
carboplatin. cvclophosphamide. carmustine. melphalan and 5-
fluorouracil on haematopoietic progenitor cells (Wasserman et al.
1981). Three clinical studies. which include two randomized phase
III trials. show- that amifostine is able to significantlv decrease the
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haematological and non-haematological toxicity of cyclophos-
phamide. carboplatin or cisplatin and cyclophosphamide (Gloxer
et al. 1986: Betticher et al. 1995: Kemp et al. 1996). At present.
only few data are axailable on the capabilitv of amifostine in
prexenting in vitro toxic effects induced in normal human progen-
itors by chemotherapeutic agents different from alkylating agents
(List et al. 1996). In the present study. we exaluated the chemopro-
tective effect of amifostine on unfractionated and purified CD34+
haematopoietic progenitors exposed to carboplatin. etoposide.
doxorubicin and taxotere.
MATERIALS AND METHODS
Peripheral blood progenitor cell (PBPC) collection and
isolation of PB mononuclear cell (PBMC) and PB
CD34+ cells
Patients with hiah-risk breast and oxarian neoplasms. prexviously
untreated with chemotherapy or radiotherapy. w-ere treated w-ith
a prexviously described cxtoreductix e/mobilizine regimen and
recombinant human granulocyte colony-stimulating factor (rhG-
CSF: Filgrastim) at the dose of 5 jcg kL- for 14 days following
chemotherapy (Menichella et al. 1994). Leukaphereses Awere
started w-hen the PB CD34+ cell count exceeded the threshold
xalue of 20 x 1W1-1 and performed using an automated blood cell
separator as prex iously described (Pierelli et al. 1993 . Aliquots of
leukapheresis products were subjected to gradient cell separation
using centrifucation (400g for 30 mn at 21'C) and a
Ficoll-Paque gradient (1.077 ml-'. Pharmacia LKB. Uppsala.
1024In vitro haematoprotection byamifostine 1025
Swxeden). PBMC xxere collected and xxashed tu-ice wxith
Ca>+/Mu'-free phosphate-buffered saline supplemented with 1%c
human albumin (PBSha). Aliquots of PBMC collected under
mobilizing conditions wxere used as a parallel source of purified
PB CD34+ cells using a prexiouslI described isolation method
(Pierelli et al. 1997).
Amifostine pre-treatment and subsequent drug
exposure of unfractionated PBMC and PB CD34+ cells
before in vitro culture
Unfractionated PBMC as xell as pre-cultured PB CD34+ cells
were incubated for 30 min at 370C xith amifostine at the dose of
30 pgnrl m (xxhich approximates the peak plasma levels achiex able
in vixo xxith a dose of 910 mg m-: List et al. 1996) adjusting cell
concentration to approximatelv 10 x I0W ml' in a 15 ml tube in
Iscove modified Dulbecco's medium (IMDM)/10%/c fetal bovine
serum (FBS). After incubation. cells wxere wxashed twice w-ith
IMDM/l'Xc FBS and then resuspended using the same medium.
Untreated controls underx ent the same manipulations of
amifostine-treated samples except that saline was substituted for
amifostine. Amifostine-treated and control cells xxere subse-
quently incubated with carboplatin (2-20 jge ml). etoposide (1-
5priml-l). doxorubicin (0.1-1.0 gml-') and taxotere (50-
250 n.\) or wxith the respective vehicles as controls (saline for
carboplatin. etoposide and doxorubicin. and DMSO for taxotere)
at 37-C in IMDM/107c FBS for 1 h or 4 h. using PBMC or PB
CD34+ cells respectively. Cells were then washed and resus-
pended in growth medium. Most drug doses used in this studv can
be reached as peak plasma levels during their in x-ixo administra-
tion. Additional growth experiments were performed as described
aboxe by culturing PB CD34+ cells in liquid medium following
pre-treatment with 1 mm N-acetxlcysteine and subsequent expo-
sure to doxorubicin.
Cloning assay
Semisolid aaar culture (clonina assay) was used to evaluate the
effect of amifostine on mveloid colony-forming unit (CFU).
Cloning assays x were established using unfractionated PBMC
collected under mobilizinr conditions as described aboxe. Txxo
hundred thousand PBMC wxere seeded into 1 ml of complete
arowth medium which consisted of IMDM supplemented with
25%7 FBS and 0.3%7 agar. Interleukin 3 (IL-3) (20 ng ml':
Genzy me. Cambridge. MA) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (20 ng ml-': Schering-Plough. Milan.
Italy) x ere used as colonv-stimulatinc actix-it7. The numberofCFUT
x as then evaluated as cell aggregates ofat least 40 elements after a
14-day culture period at 37 C in 5%7c carbon dioxide/95%7e air.
Liquid culture
Liquid cultures of precultured PB CD34+ cells wxere set up to
analy se the cyclinc status. DNA fragrmentation. replication rate
and the immunophenotype throughout the entire culture period
after amifostine and drug treatments. Precultured PB CD34+ cells
consisted of 3-day expanded freshly isolated PB CD34+ cells
xxhich were grenerated using liquid cultures wxith IMDM/25%7e
FBS in 24-well plates and in the presence of LL-3 20 ng ml-'
(Genzy-me). GM-CSF 20 nn mFl' (Schering-Plough). G-CSF
20 ncg ml-' (Sigma. Milano. Italy) and SCF 10 nr mFl' (StemCell
Table 1 Doxorubicin uptake/efflux as measured by flow cytometry in
immunoselected viable (PI) CD34+ cells and in normal human lymphocytes
Treatnt Dose CD34+ Lymphocytesa
(ug m[l) celisa
Doxorubicin 0.10 -1 +50
0.25 +20 +224
1.00 +66 +663
Amifostine/doxorubicin 0.10 -3 +46
0.25 +19 +118
1.00 +62 +580
aPer cent variation of the mean fluorescence channel compared with saline-
treated controls using doxorubicin as fluorescent tracer.
Technologies. Vancouver. BC. Canada). After the exposure to
study substances. precultured PB CD34+ cells ,A-ere reseeded at
lIW cells ml-' using 24-well plates and an identical growth medium
to that used for preculture. Cells w-ere then cultured at 37C. 5%7c
carbon dioxide/95%7 air. One-millilitre aliquots were har-vested at
each indicated time point for cell countings and flow c-tometric
analysis. Cell countings Axere performed by evaluatina viable cells
(trypan blue exclusion) in triplicate in a Neubauer chamber.
Analysis of cell replication rate during liquid cultures
The analysis of the cell replication rate wvas performed following
the procedure detailed by Lions and Christopher (1994) using flowx
cytometn and the fluorescent probe 5-6carboxyfluorescein diac-
etate succinimidvl ester (CFDA-SE: Molecular Probes. Eugene.
OR. USA). CFDA-SE is an intracellular fluorescent probe which
halves upon each cell division into daughter cells. Residual fluo-
rescence w-as then detected on each experimental day bv cytofluo-
rimetric analvsis. Ten thousand cells were acquired using an
EPICS XL flow cvtometer (Coulter. Miami. FL. USA). Liaht
scatter and propidium iodide (2 jgc ml-') were used to gate out
non-xviable cells from the analy-sis.
Cell cycle analysis and apoptosis assessment during
liquid cultures
Cell cy cle status was analysed on isolated nuclei preparations to
avoid interference from cytoplasmic components in samples
obtained from liquid cultures ofPB CD34+ cells in the presence of
study substances. as described prexiously (Ferlini et al. 1995).
DNA analysis was performed bv acquiring up to 15 000 events
usinc an EPICS XL flow cvtometer (Coulter) and a doublet exclu-
sion gate so that the analysis was performed only on single nuclei.
For the flow cvtometric assessment ofapoptosis. cell nuclei with a
hypodiploid DNA content were quantified following a prexiouslv
described procedure (Darzynkiewicz et al. 1997).
P-glycoprotein (Pgp)-related transport of doxorubicin
Immunoselected CD34+ cells were incubated in the presence or
the absence of amifostine as described in Materials and methods.
loaded with 0.1. 0.25 and 1 jg ml-' doxorubicin at 37°C for 4 h.
washed and then analy-sed by flow cvtometrx. as described
prexiouslv (De Vincenzo et al. 1996). Controls included normal
peripheral blood l1mphoc%tes incubated xxwith amifostine and/or
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Figure 1 Amifostine effect on PBMC-denved CFU exposed for 1 h to different doses of etoposede, carboplatin. doxorubcin and taxotere. Y-axis represents the
percentage of CFU growth observed at the different dose levels compared with untreated control (considered as 100% of growth). Results are expressed as the
means + s.d. observed in seven different consecutive experiments established from seven different consecutive patients. 'P < 0.05 at post hoc Fisher PLSD
test of analysis of variance (ANOVA)
doxorubicin for the same conditions of time and temperature.
Background fluorescence was assessed by omitting doxorubicin
from the incubation medium.
Statistical analysis
Results were compared using analysis of variance (ANOVA) and
Fisher PLSD test as post hoc ofANOVA to identify significant differ-
ences between treatments. A P < 0.05 was considered significant.
RESULTS
Amifostine chemoprotection on CFU established from
unfractionated PBMC
Amifostine alone showed no effect on the CFU formation from
PBMC. Similarly. no effect of the taxotere vehicle DMSO w-as
observed. Because the commercial formulation of amifostine
contains mannitol as an excipient. parallel experiments were
performed using a mannitol concentration corresponding to that
contained in 30 go ml-' of amifostine and they showed that
mannitol alone does not significantly affect CFU growth and does
not protect CFU from the toxic effect of the different drugs.
Concentrations of chemotherapeutic agents which produced a
CFIJ growth inhibition encompassed between 30%7 and 70% in
cloning assays and those concentrations which were of the same
magnitude of drug plasma peaks achiesable in sivo were selected
(Figure 1). Figure 1 shows that amifostine pretreatment at
30 jig ml-' produced a significant chemoprotection in etoposide-
carboplatin-. and taxotere-treated CFIJ. Chemoprotection from
etoposide appeared to be more evident and statistically significant
at the lowest etoposide doses (1 and 2 igo ml-'). whereas
amifostine was more active with high dosages of carboplatin and
taxotere (8 and 20 jgc ml-' and 250 nst respectively). Conversely.
amifostine pretreatment did not produce any protectise effect on
doxorubicin-exposed cloning progenitors at all doses tested
(Figure 1f. In fact. amifostine produced a consistent potentiation of
doxorubicin cvtotoxicitv on treated CFU. hich produced a signif-
icant decrease ofCFU growth at doxorubicin doses of0.25 jgc ml-'
and 1 ml- (Figure 1).
Amifostine chemoprotection of PB CD34+ cell cultures
in liquid medium
Precultured PB CD34+ cells consisted of 3-day cultured PB
CD34+ cells in the presence of IL-3. GM-CSF. G-CSF and SCF.
Of these cells. 80 ± 6% still expressed the CD34 antigen and
60 ± 5%7 were in GJG1. whereas 40 ± 5 were in S/G,/M phase of
the cell cycle on average. These cells were used to assess the
amifostine and drug effects on haematopoietic progenitors in
liquid culture. The amifostine excipient mannitol did not si2nifi-
cantly affect PB CD34+ cell growth and did not exert any chemo-
protection on these cells. Amifostine provided a significant
chemoprotection for both etoposide-treated (2 jge ml-' ) and carbo-
platin-treated (4 g l-l') PB CD34- cells in liquid culture. abro-
gating their myelotoxic effect at any time point of culture (Figure
2) in five different consecutive experiments. Conversely. amifos-
tine pretreatment produced a consistent detrimental effect on
growth of doxorubicin-treated (0.25 jg^ ml-') PB CD34+ cells.
confirming the results observed in PBMC-derived CFU (Figure 2).
Amifostine did not protect PB CD34+ cells exposed to taxotere
using a taxotere dose of 50 nst. which produced a 50% growth
inhibition of PB CD34+ cells. Taxotere doses higher than 50 n-Mi
produced a complete growth inhibition of PB CD34+ cells. Figure
3 shows that at 1 mm the antioxidant compound N-acetylcysteine
produced a similar potentiation ofthe myelotoxic effect ofdoxoru-
bicin to that exerted by amifostine during liquid culture of PB
CD34+ cells in five different consecutive experiments.
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Figure 2 Amifostine effect on growth in liquid culture of PB CD34+ cells exposed for 4 h to etoposide (2 gg ml-'), carboplatin (4 jg ml-'), doxorubicin
(0.25 jg ml-) and taxotere (50 rn). yoaxis represents the number of cells observed at the indicated time point of cutture in the different culture condifions.
Results are expressed as the means ± s.d. observed in five different consecutive experiments established from five different consecutive patients. *P < 0.05 at
post hoc Fsher PLSD test of analysts of variance (ANOVA)
Apoptosis, cell cycle and cell replication rate during
liquid culture of PB CD34+ cells in the presence or the
absence of study substances
Amifostine pretreatment was unable to considerably modify the
DNA fragmentation profile of etoposide-. carboplatin-. doxoru-
bicin- and taxotere-exposed PB CD34+ cells on days 3. 5 and 7 of
culture (data not shown). The analysis of the cell cycle indicated
that amifostine did not modify the distribution of cells in the
different cell cycle phases when this compound was used alone or
before PB CD34+ cell exposure to etoposide. carboplatin or
taxotere (data not shown). Conversely. an increased G,JM phase
was observed in amifostine/doxorubicin-treated PB CD34+ cells
compared with saline/doxorubicin-treated PB CD34+ cells. This
effect was particularly evident on day 3 of culture and it was
accompanied by a concomitant decrease of S phase [G,/M (%) =
7 ± 2 for doxorubicin, 12 ± 2 for amifostine/doxorubicin. 3.6 ± 1
for amifostine and 3.4 ± 1 for saline; P < 0.05 for doxorubicin vs
amifostine/doxorubicin at post hoc Fisher PLSD test of ANOVA].
The analysis of cell replication rate of viable cells confirmed that
in amifostine/doxorubicin-treated PB CD34+ cells the increased
G,/M phase did not translate into a proportional increase of cell
replication rate. suggesting that cells accumulate in this phase as a
consequence of a toxic G,/M arrest (data not shown). To note.
amifostine increased the number of dead cells (identified using
both trypan blue exclusion test and propidium iodide viability test
by flow cytometry) in doxorubicin-treated cells on day 3 (viable
cells = 73 + 10% for doxorubicin and 59 ± 11% for amifostine
n
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Figure 3 N-acetycysteine (1 mu) effect on growth in liquid culture of PB
CD34+ cells exposed for 4 h to doxorubicin (0.25 jg mlt-). y-axis represents
the number of cells observed at the indicated bme point of culture in the
different culture cordibons. Results are expressed as the means ± s.d.
observed in five different consetive experiments established from five
different consecuti patients. * P <0.05 at posthoc Fsher PLSD test of
analysis of varance (ANOVA)
doxorubicin). day 5 (viable cells = 75 ± 9% for doxorubicin and
69 ± 14% for amifostine/doxorubicin) and day 7 ofculture (viable
cells = 91 ± 4% for doxorubicin and 66 + 16% for amifostine/
doxorubicin: P < 0.05 at post hoc Fisher PLSD test of ANOVA).
Finally. we observed very similar profiles of CFDA-SE fluores-
cence decline of viable cells in all the experimental conditions we
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studied. suggesting that neither drug exposure nor amifostine
pretreatment followed by drugr exposure considerably affected the
replication rate of PB CD34+ cells which survived the toxic effect
produced by etoposide. carboplatin. doxorubicin and taxotere (data
not shown).
Amifostine pretreatment and Pgp-related transport of
doxorubicin
Because amifostine potentiated the activity of doxorubicin. we
evaluated its potential effect on Pgp activity by flow cytometry.
Results indicated that amifostine exerted no significant effect on
the Pgp pump efflux activity (Table 1). CD34+ cells accumulated
considerably less doxorubicin than normal lymphocytes. but this
capacity was not influenced by amifostine at all doxorubicin
concentrations tested.
DISCUSSION
Preclinical studies in mice showed that amifostine pretreatment
consistently decreases the toxic effect of radiation. nitrogen
mustards. cisplatin. cyclophosphamide. carmustine. melphalan
and 5-fluorouracil on haematopoietic progenitor cells (Wasserman
et al. 1981). Recently. Shpall et al (1994) and Douay et al (1995)
demonstrated that amifostine pretreatment protects human bone
marrow CFU and lono-term culture-initiating cells (LTC-IC) from
mafosfamide or 4-hydroperoxycyclophosphamide (4-HC) treat-
ment. Collectively. these data suggest that amifostine exerts a
significant myeloprotective effect from toxicity produced by
radiation. 5-fluorouracil and alkylating, agents. These results were
confirmed in three clinical studies in which amifostine signifi-
cantly reduced the haematological toxicity of cyclophosphamide.
carboplatin orcisplatin and cyclophosphamide (Glover et al. 1986:
Betticher et al. 1995: Kemp et al. 1996). In this study. we tested the
effectiveness of amifostine pretreatment in protecting unfraction-
ated and purified human haematopoietic progenitors exposed to
carboplatin. etoposide. doxorubicin and taxotere.
Unfractionated progenitor cultures in semisolid medium
showed that a consistent and significant protective effect is
produced by amifostine pretreatment on carboplatin. etoposide and
high-dose taxotere (250 n.x. which corresponds to the plasma peak
levels achievable in vivo administering 70 m, m-' ofdrug: Bisset
et al. 1993) exposed progenitors. Surprisingly. amifostine pretreat-
ment significantly worsened the myelotoxic effect ofdoxorubicin.
These results suggest that chemoprotection by amifostine is a
drug-dependent process rather than an indefinite optimization of
growth of those haematopoietic progenitors which escaped the
toxic damage produced by the different agents. Liquid cultures of
PB CD34+ cells confirmed that a significant chemoprotection can
be produced by amifostine in etoposide- and carboplatin-treated
progenitors. The detrimental effect exerted by amifostine on
doxorubicin-exposed progenitors was documented also in this
model of in vitro progenitor growth. This detrimental effect
became evident from the 5th day of liquid culture onward with an
evident decline of cell growth compared with doxorubicin alone.
suggaesting that the enhancement of doxorubicin toxicity by
amifostine was the result of a progressive inability of cells to
adequately proliferate in response to growth factor stimulation
during, culture rather than a greater cell killing immediately after
drug exposure. Liquid cultures made possible the monitoring of
apoptotic events, cycling status and viable cell replication rate (by
progressive halving, ofa fluorescent dve) during etoposide-. carbo-
platin- and doxorubicin-exposed PB CD34+ cell growth in -itro
after amifostine pretreatment. as well as in controls. The body of
these data suggests that in etoposide- and carboplatin-treated pro-
genitors amifostine pretreatment does not considerably affect the
number of apoptotic events. the cell distribution into the different
phases of the cell cycle and the number of cell div-isions of v-iable
cells from day 3 ofculture onward. This fact suagests that amifos-
tine produces a specific protection from etoposide and carboplatin
toxic effects. increasingr the fraction ofcells which survive the cell
damage generated by these drugs. Progenitor rescue after drug
treatment could be mediated by the previously documented abilitv
of amifostine to bind the active species of platinum agents. to
reverse platin-DNA adduct formation and to repair DNA by
hydrogen atom transfer or oxygen depletion (Purdie and Inhaber.
1983: Willson et al. 1983: Treskes and van der Vijgh. 1993).
Conversely. in doxorubicin-exposed PB CD34+ progenitors.
amifostine pretreatment produces an accumulation of cells in the
GJM phase of the cell cycle in the absence of a proportional
increase in the viable cell division number. and in the presence of
an increased number of dead cells in the cultures. This fact
suaaests that amifostine enhances the capacity of doxorubicin to
produce cell death through a GJM arrest. which is a well-known
dose-dependent cytokinetic effect of anthracyclines (Bartkowiak
et al. 1992). This study also shows that doxorubicin potentiation
by amifostine is not mediated by an increased retention ofdoxoru-
bicin. a possibility which must be excluded because haematopoi-
etic progenitors are characterized by an active Pgp-mediated efflux
system (Chaudhary and Roninson. 1991). On the whole. these data
support the hypothesis that the potentiation of doxorubicin
haematopoietic toxicity by amifostine in vitro could lie in the
increased intracellular availability of free exogenous thiols which
are known to catalyse the generation of hydrogen peroxide and
hydroxyl radicals in the presence of a doxorubicin-iron complex
(Muindi et al. 1985). or alternatively in the reported capacity of
amifostine to reduce intracellular glutathione levels (Issels and
Nagaele. 1989: Meier and Issels. 1995). Using liquid cultures ofPB
CD34+ cells. we found that pretreatment with N-acetylcysteine
produces an increase of the toxic effect of doxorubicin as well as
amifostine does. The antioxidant nature of both compounds
confirms that the detrimental effect on cell growth is probably due
to a greater intracellular availability of exogenous antioxidant
compounds. Therefore. our data suggest caution in the combined
use of amifostine and doxorubicin until their pharmacological
interaction can be fully clarified. Preliminary data from our labora-
tory indicate that amifostine does not worsen the myelotoxic effect
of epirubicin. daunorubicin and mitoxantrone on purified PB
CD34+ cells. and these preliminary findings are in harmony with
the observations made by List et al (1996). Finally. our in vitro
data on amifostine haematoprotection after treatments with etopo-
side. carboplatin and taxotere and the previously reported works
on the chemoprotection of normal tissue after treatment with
several chemotherapeutic agents encourage the clinical use of
amifostine in preventinc toxicity ofanticancer therapy.
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